TMC-310911

Edit links
Source: Wikipedia, the free encyclopedia.
(Redirected from
ASC-09
)
TMC-310911
Legal status
Legal status
  • US: Investigational drug
Identifiers
  • [(3As,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[[2-[(1-cyclopentylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl]sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
JSmol)
  • CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC5=C(C=C4)N=C(S5)NC6CCN(CC6)C7CCCC7
  • InChI=1S/C38H53N5O7S2/c1-25(2)22-43(23-33(44)32(20-26-8-4-3-5-9-26)41-38(45)50-34-24-49-36-30(34)16-19-48-36)52(46,47)29-12-13-31-35(21-29)51-37(40-31)39-27-14-17-42(18-15-27)28-10-6-7-11-28/h3-5,8-9,12-13,21,25,27-28,30,32-34,36,44H,6-7,10-11,14-20,22-24H2,1-2H3,(H,39,40)(H,41,45)/t30-,32-,33+,34-,36+/m0/s1
  • Key:JQUNFHFWXCXPRK-AMMMHQJVSA-N

TMC-310911 (also known as ASC-09) is an

AIDS. It is a protease inhibitor related to darunavir.[1][2] While TMC-310911 was not ultimately developed as a medication for the treatment of AIDS, research has continued into potential applications in the treatment of other viral diseases, and in March 2020 it was entered into clinical trials for the treatment of COVID-19.[3][4]

See also

References

  1. PMID 21896904
    .
  2. PMID 25565044
    .
  3. doi:10.26434/chemrxiv.12011157.v3
    .
  4. ^ McGrath J (2 April 2020). "All the COVID-19 vaccines and treatments currently in clinical trials". Digital Trends. Retrieved 6 April 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=TMC-310911&oldid=1215136392"
This page is based on the copyrighted Wikipedia article: ASC-09. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy